Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 3Thoracic 2Head & Neck 2Gynecologic 2Dermatologic 2CNS 1Breast 1

Conditions

Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 4Stomach Neoplasms 3Ovarian Neoplasms 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Melanoma 2Carcinoma, Renal Cell 2Breast Neoplasms 2Brain Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Neoplasm Metastasis 1Kidney Neoplasms 1Histiocytosis 1Head and Neck Neoplasms 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 63Nivolumab 44atezolizumab 14Docetaxel 10Cyclophosphamide 10Paclitaxel 9Magnetic Resonance Spectroscopy 9Ipilimumab 9avelumab 8Specimen Handling 8durvalumab 7Radiosurgery 7Cetuximab 7spartalizumab 6Radiotherapy 6Immune Checkpoint Inhibitors 6Interleukin-2 5Carboplatin 5fludarabine 4cabozantinib 4Trastuzumab 4Sunitinib 4Psychiatric Rehabilitation 4Pemetrexed 4Oxaliplatin 4Fluorodeoxyglucose F18 4Everolimus 4Cisplatin 4Capecitabine 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × IFL protocol × Thoracic × Clear all
NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡